Table 2.
Clinical Characteristics of the Patient Sample (N = 430)
| Characteristic | n (%) |
|---|---|
| Diagnosis | |
| Leukemia | 140 (32.9%) |
| ALL | 27 (19.3%) |
| AML | 66 (47.1%) |
| CLL | 10 (7.1%) |
| CML | 5 (3.6%) |
| MDS | 32 (22.9%) |
| Lymphoma | 134 (31.5%) |
| Non-Hodgkin | 107 (79.9%) |
| Hodgkin | 27 (20.1%) |
| Multiple myeloma | 130 (30.5%) |
| Aplastic anemia | 5 (1.2%) |
| Other | 17 (4.0%) |
| Transplant type | |
| Autologous | 243 (57.0%) |
| Allogeneic | 183 (43.0%) |
| Conditioning regimen a | |
| Fully ablative | 123 (67.2%) |
| Reduced intensity | 60 (32.8%) |
| Number of comorbid conditions | |
| 0 | 83 (26.9%) |
| 1 | 46 (14.9%) |
| 2 | 71 (23.1%) |
| 3 | 57 (18.5%) |
| 4 | 28 (9.1%) |
| 5 | 10 (3.2%) |
| 6 | 8 (2.6%) |
| 7 | 2 (0.6%) |
| 10 or more | 3 (1.0%) |
| Chronic graft-versus-host-disease (cGVHD) a | 92 (55.8%) |
| Acute graft-versus-host disease (aGVHD) a | 92 (52.6%) |
| Infections b | 181 (48.3%) |
Note. Numbers for some clinical characteristics add up to less than 430 due to data that were unavailable in the patient record. CML = chronic myeloid leukemia; CLL = chronic lymphocytic leukemia; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; MDS = myelodysplastic syndrome.
a
Allogeneic stem cell recipients only (n = 183)
b
Presence of infection(s) pretransplant to 1-month posttransplant